microdosing glp 1 tirzepatide GLP-1 Chart: and Semaglutide Women's Microdosing & Weight Maintenance

In the STEP 1 trial, participants taking a 2.4 mg weekly dose achieved a mean total body weight reduction of 14.9 percent over 68 weeks (Source: STEP 1 Trial, Wilding et al., NEJM 2021)

A 2021 study in published in NEJM of obese adults that used once-weekly injections found weight loss by 10% or more

Though we are developing both Semaglutide & Tirzepatide biosimilars, it will be fascinating to watch how these molecules redefine the oral GLP-1 category once the sema 25 mg data become widely published

For statistical analysis, continuous data were summarized as means SD or medians with IQR, contingent on data distribution, and compared using appropriate tests such as the Student t-test or Wilcoxon Rank Sum test

Im in disbelief about my results

If nausea persists at this stage, staying at your current dose longerrather than escalatingoften resolves it within another week